Analyst Price Targets — ADXN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 28, 2024 6:49 am | Raghuram Selvaraju | H.C. Wainwright | $30.00 | $10.52 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Addex Therapeutics (ADXN) |
Latest News for ADXN
Addex Therapeutics Ltd. Sponsored ADR (NASDAQ: ADXN - Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 11,951 shares, a growth of 137.6% from the February 12th total of 5,030 shares. Currently, 1.1% of the company's stock are sold short. Based
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ADXN.
Senate Trading
No Senate trades found for ADXN.
U.S. House Trading
No House trades found for ADXN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.